openPR Logo
Press release

Clues to HIV Persistence on ART

08-24-2011 09:00 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: AVPS

/ PR Agency: Straight Line PR
Recent research has found that while antiretroviral therapy (ART) is effective at significantly reducing the number of plasma-to-T-cell transmissions of HIV, it's not as effective against T-cell-to-T-cell. The remaining virus hides in infected T-cells, which allows it to easily be passed on to non-infected ones; this, in fact, is one of the reasons why HIV persists through ART.

Toulon, France, August 23, 2011 - HIV has a built-in backup plan when it comes to its survival. While scientific technology has progressed to the point where antiretroviral drugs can effectively kill HIV viruses in the body that are out in the open, HIV persists in places where the drugs can't get to them. These places are called HIV reservoirs, and these reservoirs ensure that small batches of virus remain in the body, ready to replicate when necessary. This is part of what makes HIV a chronic infection—the remaining virus finds ways to remain dormant in the body until activated. Research is now focusing on cracking the case of HIV persistence.

The goal of researchers now is to remove the "chronic" term from the chronic illness that is HIV and come up with a cure for the disease. A better understanding of HIV and how it infects people to begin with might be the key to discovering ways to enter the reservoirs within the body and eliminate the virus. As we already know, HIV infects cells in two ways: through blood plasma contact with T-cells, and from infected T-cells to non-infected T-cells. Antiretroviral drugs, while effective, don't remove the entire virus quantity, and all it takes is for one HIV virus to remain behind for the replication to continue.

Recent research has found that while antiretroviral therapy (ART) is effective at significantly reducing the number of plasma-to-T-cell transmissions of HIV, it's not as effective against T-cell-to-T-cell. The remaining virus hides in infected T-cells, which allows it to easily be passed on to non-infected ones; this, in fact, is one of the reasons why HIV persists through ART. To use a football analogy, ART is able to intercept passes through the air (plasma) from one cell to another, but it can't stop direct handoffs. A strategy is needed to defend against each separately, because the same defense can't be used against both.

Even with antiretroviral drugs present, infected T-cells can still infect other T-cells in close quarters instead of through the bloodstream; this often happens in the lymph nodes. Therefore, in order to find an actual cure for HIV, researchers need to find a way to deal with HIV reservoirs filled with both latent HIV virus and active virus that is transmitted from cell-to-cell. The clues to HIV persistence are clear, but this is one of those situations where the answer seems obvious but the path toward deriving the answer is extremely difficult.

Alain Lafeuillade
1208 avenue Colonel Picot
Toulon 83100 France

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Clues to HIV Persistence on ART here

News-ID: 188929 • Views: 1726

More Releases from AVPS

09-09-2011 | Health & Medicine
New Trends Towards HIV Cure Research
Fifteen years after the advent of combined antiretroviral therapy (ART) life expectancy of HIV-infected patients, as well as their quality of life, have considerably improved. However, ART remains a life long battle as these therapies are unable to eradicate the virus. Although we can still improve tolerance and acceptability of ART, the next decisive step would be to find a cure. Specific budget lines have been created in 2010 and
Approaches to HIV Eradication
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a cure against HIV lies in dealing with HIV reservoirs. Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress
01-14-2011 | Health & Medicine
HIV Reservoirs Cure Research – More Investments Are Needed
Toulon, France, January 12, 2010 -- With great effort and research into how to fight the HIV virus, important advancements in treatment have been made. What used to be a near-automatic death sentence is no longer the case. With the right mixture of medicines, an HIV-positive person can now live much longer than before. The HIV asymptomatic periods are now much longer than before as well, thanks to HIV research.

All 4 Releases

More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral